Novedades
SOM Biotech completa el proceso de reclutamiento en el estudio de fase IIb del tratamiento de la corea en la enfermedad de Huntington
SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Phase IIb clinical study with SOM3355 as a treatment for Huntington’s chorea has been completed. After a a Phase IIa study where the Leer más...